- March 15, 2019
- Category: What's New
March 13, 2019 — Radiation oncology and nuclear medicine software developer DOSIsoft has received U.S. Food and Drug Administration (FDA) 510(k) clearance to market its Planet Onco Dose software for molecular imaging and molecular radiotherapy dosimetry applications.
The software, which had previously received the CE Mark, features components that support dosimetry for selective internal radiation therapy (SIRT) with yttrium-90 microspheres. It’s intended to help assist users to diagnose, quantify, and verify radiation doses received by tissues as a result of administering yttrium-90 microsphere implants, as well as aid in therapy response follow-up, according to DOSIsoft. A modular software suite, Planet Onco Dose comprises the Planet Onco oncology module and the Planet Dose dosimetry module.
Planet Onco enables the review of multimodality molecular imaging series, fusion and registration, automatic and semi-automatic contouring of regions of interest, tumor segmentation, quantification, tumor activity monitoring, and therapy response assessment, according to the vendor. Meanwhile, Planet Dose provides 3D personalized voxel-based internal dosimetry computation for molecular radiotherapy procedures, the company said.